Your search for non small cell lung cancer returned 7 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Mpr-drug-news remove
Da Hee Han, PharmD remove
Drugs in the Pipeline remove

Your search for non small cell lung cancer returned 7 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

New Pemetrexed Formulation to Be Reviewed by FDA

The NDA proposes the use of ready-to-dilute pemetrexed injection for the treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and mesothelioma (in combination with cisplatin).
Drugs in the Pipeline

Brigatinib NDA Accepted for FDA Review

ARIAD announced that the Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for brigatinib to treat patients with metastatic ALK+ non-small cell lung cancer (NSCLC) who have progressed on crizotinib.
Drugs in the Pipeline

Imfinzi Designated Breakthrough Therapy for NSCLC

Imfinzi, an anti-PD-L1 monoclonal antibody, was previously granted accelerated approval from the FDA for locally advanced or metastatic urothelial carcinoma in patients who have disease progression during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
Drugs in the Pipeline

FDA to Review Opdivo for Urothelial Carcinoma Use

Bristol-Myers Squibb announced that the Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) for Priority Review.